Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...

Having already acquired UK-based Cambridge Antibody Technology in 2006 ... After rejecting Pfizer, AstraZeneca continued with its own M&A ambitions, and in the following years the company saw ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market ... Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others are ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

That timeframe would make Pfizer's vaccine an alternative to antibody-based therapies that ... RSV in the crucial first few months of life. AstraZeneca and Sanofi are out in front in this category ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...